Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas

Leukemia and Lymphoma

Volumn 29, Issue 1-2, 1998, Pages 139-144

  Navaratnam, Srisala ^a   Williams, Gaynor J ^a   Rubinger, Morel ^a   Pettigrew, Norman M ^a   Mowat, Michael R A ^a   Begleiter, Asher ^a   Johnston, James B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Clinical response; Immunohistochemistry; Non Hodgkin's lymphoma; p53

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; PREDNISONE; PROTEIN P53; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE;

EID: 0031860937     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809058389     Document Type: Article

References (31)

1. Rabkin, C. S., Devesa, S. S., Zahm, S. H. and Gail, M. H. (1993). Increasing incidence of non-Hodgkin's lymphoma. Semin. Hematol., 30, 286-296.
2. DeVita, V. T., Canellos, G. P. and Chabner, B. (1975). Advanced diffuse histiocytic lymphoma, a potentially curable disease. Results with combination chemotherapy. Lancet, 1, 248-250.
3. McKelvey, E. M., Gottlieb, J. A. and Wilson, H. E. (1976). Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer, 38, 1481-1493.
4. Schein, P. S., De Vita, V. T. and Hubbard, S. (1976). Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann. Intern. Med., 85, 417-422.
5. Gordon, L. I., Harrington, D., Andersen, J., et al. (1992). Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with the standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N. Engl. J. Med., 19, 1342-1349.
6. Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A. Jr. and Miller, T. P. (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med., 328, 1002-1006.
7. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993). A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med., 329, 987-994.
8. Shipp, M. A. (1993). Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood, 83, 1165-1173.
9. Selivanova, G. and Wiman, K. G. (1995). p53: A cell cycle regulator activated by DNA damage. Advances in Cancer Res., 66, 143-180.
10. Lowe, S. W., Ruley, H. E., Jacks, T. and Housman, D. E. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967.
11. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. and Jacks, T. (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362, 847-849.
12. Fan, S., El Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J. Jr., Magrath, I., Kohn, K. W. and O'Connor, P. M. (1994). p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54, 5824-5830.
13. El Rouby, S. A., Thomas, A. D., Costin, D., Rosenberg, C. R., Potmesil, M., Silber, R. and Newcomb, E. W. (1993). p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood, 82, 3452-3459.
14. Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., Volkmann, M., Galle, P. R., Poustka, A., Hunstein, W. and Lichter, P. (1995). p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 85, 1580-1589.
15. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. and Fenaux, P. (1994). p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148-3157.
16. Louie, D. C., Offit, K., Jaslow, N. R., Parsa, N. Z., Murty, V. V. V. S., Schluger, A. and Chaganti, R. S. K. (1995). p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood, 86, 2892-2899.
17. Chang, F., Syrjanen, S. and Syrjanen, K. (1995). Implications of the p53 tumor-suppressor gene in clinical oncology. J. Clin. Oncol., 13, 1009-1022.
18. Villuendas, R., Pins, M. A., Algara, P., Sanchez Beato, M., Sanchez Verde, L., Martinez, J. C., Orradre, J. L., Garcia, P., Lopez, C. and Martinez, P. (1993). The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood, 82, 3151-3156.
19. Kocialknowski, S., Pezzella, F., Morrison, H., Jones, M., Laha, S., Harris, A. L., Mason, D. Y. and Gatter, K. C. (1995). Mutations in the p53 gene are not limited to classic 'hot spots' and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br. J. Haematol., 89, 55-60.
20. Piris, M. A., Villuendas, R., Martinez, J. C., Sanchez-Beato, M., Orradre, J. L., Mateo, M. S. and Martinez, P. (1995). p53 Expression in non-Hodgkin's lymphomas: A marker of p53 inactivation? Leuk. Lymph., 17, 35-42.
21. Maestro, R., Gloghini, A., Doglioni, C., Gasparotto, D., Vukosavljevic, T., De Re, V., Laurino, L., Carbone, A. and Boiocchi, M. (1995). MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. Blood, 85, 3239-3246.
22. Meyer, R. M., Quirt, I. C., Skillings, J. R., Cripps, M. C., Bramwell, V. H. C., Weinerman, B. H., Gospodarowicz, M. K., Burns, B. F., Sargeant, A. M., Shepard, L. E., Zee, B. and Hryniuk, W. M. (1993). Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N. Engl. J. Med., 329, 1770-1776.
23. Resnick, J. M., Cherwitz, D., Knapp, D., Uhlman, D. and Niehans, G. A. (1995). A microwave method that enhances detection of aberrant p53 expression in formalin-fixed, paraffin-embedded tissues. Arch. Pathol. Lab. Med., 119, 360-366.
24. Armitage, J. O. (1993). Treatment of non-Hodgkin's lymphoma. NEJM, 328, 1023-1030.
25. Lepelley, P., Preudhomme, C., Vanrumbeke, M., Quesnel, B., Cosson, A. and Fenaux, P. (1994). Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia, 8, 1342-1349.
26. Zastawny, R. L., Salvino, R., Chen, J., et al. (1993). The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene, 8, 1529-1535.
27. Yin, Y., Tainsky, M. A., Bischoff, F. Z., et al. (1992). Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70, 937-948.
28. Goker, E., Waltham, M., Kheradpour, A., et al. (1995). Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 mutations. Blood, 86, 677-684.
29. 2/M when it is transactivation defective. EMBO, 20, 4994-5005.
30. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W. and Galloway, D. A. (1996). Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Medicine, 2, 72-79.
31. Schipp, M. A., Neuberg, D., Janicek, M., Canellos, G. P. and Shulman, L. N. (1995). High-dose CHOP as intial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study. J. Clin. Oncol., 13, 2916-2923.